eli lilly glp-1 receptor agonist medications Lilly's Oral Therapy Foundayo (orforglipron) Is Now Available for Weight Loss Eli Lilly's New Oral GLP-1

JCI Insight 5 , e140532 (2020)

The drug is known as a triple-agonist, meaning it targets three different receptors in the brain and throughout the body

Cardiovascular Benefits : Emerging evidence suggests that GLP-1 drugs not only support weight loss but also significantly reduce the risk of cardiovascular events in patients with obesity and diabetes

Liraglutide is another long-acting GLP-1RA that is administered once daily

Mechanism: GLP-1, Ghrelin, and the Orexin System The mechanistic chain that connects a metabolic drug to a sleep symptom runs through the hypothalamus

To learn how Cypris can accelerate your obesity therapeutics intelligence workflows, visit cypris.ai or request a demonstration tailored to your specific pipeline and competitive monitoring needs